Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Intratumorally-Administered Topotecan Using CED in High Grade Glioma Undergoing Stereotactic Biopsy

28 de fevereiro de 2019 atualizado por: Michael Vogelbaum, MD, PhD

Pilot Trial of Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive World Health Organization (WHO) Grade III or IV (High Grade) Glioma Undergoing Stereotactic Biopsy (IND 117,240)

The purpose of this study is to determine if treatment with topotecan by an alternative method, direct delivery into brain tumors, is safe and well tolerated. The Cleveland Multiport Catheter is a new, investigational device that will be used to deliver topotecan into your brain tumor. A second purpose of this study is to determine whether the Cleveland Multiport Catheter can be used effectively and safely to deliver topotecan into your brain tumor.

This study will also determine the best dose of topotecan to deliver to your tumor with use of the Cleveland Multiport Catheter and will also examine how your tumor responds to treatment with topotecan.

Visão geral do estudo

Status

Retirado

Condições

Intervenção / Tratamento

Descrição detalhada

Primary Objectives

  • To investigate by MR imaging the spatial and temporal distribution of topotecan in enhancing or nonenhancing bulk tumor administered by convection-enhanced delivery (CED) in patients with recurrent/progressive WHO grade III or IV (high grade) glioma (HGG) who have failed standard therapy comprising surgical biopsy and/or resection and adjuvant chemotherapy and radiotherapy.
  • To investigate by MR imaging the influence of the rate and topotecan concentration, on the spatial and temporal distribution of topotecan administered by CED in patients with with recurrent/progressive HGG

Secondary Objectives

  • To investigate the extent to which backflow may be observed on MRI during CEDmediated delivery of topotecan
  • To assess the safety, tolerability and toxicity profile of topotecan administered by CED using different doses and infusion rates.
  • To observe evidence of activity of single-agent topotecan administered by CED to patients with recurrent/progressive HGG who have failed standard therapy comprising surgical biopsy and/or resection and adjuvant chemotherapy and radiotherapy.

Tipo de estudo

Intervencional

Estágio

  • Fase inicial 1

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Histologically confirmed diagnosis of supratentorial WHO Grade III or IV Glioma (High Grade Glioma) that has undergone surgical biopsy or resection followed by adjuvant chemoradiotherapy, that has evidence of recurrence or progression based on imaging studies and a stereotactic biopsy is indicated for confirmation of recurrence/progression
  • Karnofsky Performance Status 70-100
  • MRI demonstration of a stereotactically accessible enhancing mass that does not require resection to relieve clinically significant mass effect
  • Patient understands the procedures and agrees to comply with the study requirements by providing written informed consent

  • Laboratory values within the following ranges:

    • Absolute neutrophil count (ANC) ≥ 1,500 / μL
    • Platelet count ≥ 100,000 / μL
    • Hemoglobin ≥ 10 g / dL
    • prothrombin time (PT) / partial thromboplastin time (PTT) not above institutional norms
    • Estimated glomerular filtration rate (eGFR) of at least 50 mL/min

Exclusion Criteria:

  • Patient is mentally or legally incapacitated at the time of the study
  • Known HIV(+) or has been diagnosed with AIDS
  • Participation in another investigational drug study in the prior 4 weeks
  • Positive pregnancy test in a female
  • Patient, in the opinion of the investigator, is likely to be poorly compliant
  • Diffuse subependymal or cerebrospinal fluid (CSF) disease
  • Tumors involving the cerebellum
  • Tumor enhancement involving both hemispheres
  • Active infection requiring treatment
  • Unexplained febrile illness
  • Radiation or chemotherapy within 4 weeks of enrollment
  • Systemic diseases associated with unacceptable anesthesia or operative risk
  • Inability to undergo magnetic resonance imaging

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Predominantly enhancing mass with volume of 8 cc or less
Only 1 Cleveland Multiport Catheter (CMC) will be placed and CED will be performed intra-operatively only in a magnetic resonance imaging (MRI) equipped Operating Room. Topotecan infusion will be performed over a 4-hour period, with the goal of complete tumor coverage. The initial rate will be 1.20 ml/hour and infusion will be monitored by intermittent MRI imaging. The rate may be adjusted upwards during the infusion, in the event of incomplete tumor coverage, or downwards, if new mass effect is apparent. Following completion of the 4-hour infusion, the CMC will be removed. The initial rate for each subsequent patient may be adjusted upwards in increments of up to 1.20 ml/hour based upon the tumor coverage and safety characteristics of the previously treated patients.
Medicamento: Topotecan (<=8cc)
In predominantly enhancing mass with a volume of 8 cc or less of topotecan administered
Outros nomes:
  • Hycamtin
Dispositivo: Cleveland Multiport Catheter
an investigational device, will be used to deliver the topotecan
Teste de diagnostico: Magnetic Resonance Imaging (MRI)
to monitor the infusion of topotecan into the tumor
Experimental: Predominantly enhancing mass with volume of > 8 cc
2 Cleveland Multiport Catheter (CMCs) will be placed and the total infusion rate of Topotecan per CMC to be used for the first 24 hours for the first patient will be 0.834 ml/hour (3.48 microliters/minute/microcatheter). The rate used for the second 24 hours of the infusion will be 1.668 ml/hour. If the first patient does not experience rate-limiting toxicity, then the patient #2's initial infusion rate will start at the highest tolerated rate for patient #1, and the second 24-hour rate for that patient will be increased by 0.834 ml/hour. Each subsequent patient will undergo rate escalation in a similar manner until we observe either: 1) complete coverage of the enhancing tumor by the infused Gadopentetic acid (Gd-DTPA), or 2) rate-limiting toxicity.
Dispositivo: Cleveland Multiport Catheter
an investigational device, will be used to deliver the topotecan
Teste de diagnostico: Magnetic Resonance Imaging (MRI)
to monitor the infusion of topotecan into the tumor
Medicamento: Topotecan (>8cc)
In predominantly enhancing mass with a volume of > 8 cc of topotecan administered. Initial rate is 0.834ml/hour with an increase to 1.668 ml/hour at the second infusion
Outros nomes:
  • Hycamtin
Experimental: Predominantly non-enhancing mass
The total infusion rate of Topotecan per Cleveland Multiport Catheter (CMC) to be used for the first 24 hours for the first patient will be 0.29 ml/hour. The rate used for the second 24 hours of the infusion will be 0.58 ml/hour. If the first patient does not experience rate-limiting toxicity, then the patient #2's initial infusion rate will start at the highest tolerated rate for patient #1, and the second 24-hour rate for that patient will be increased by 0.29 ml/hour. Each subsequent patient will undergo rate escalation in a similar manner until we observe either: 1) complete coverage of the non-enhancing tumor by the infused Gd-DTPA, or 2) rate-limiting toxicity.
Dispositivo: Cleveland Multiport Catheter
an investigational device, will be used to deliver the topotecan
Teste de diagnostico: Magnetic Resonance Imaging (MRI)
to monitor the infusion of topotecan into the tumor
Medicamento: Lower Does Topotecan
Rate for non-enhancing tumors has an initial dose of 0.29ml/hour
Outros nomes:
  • Hycamtin

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Number of intra-operative catheter related complications
Prazo: Up to 12 months
Documentation of possible, probable, or definite catheter-related complications
Up to 12 months
Number of post-operative catheter related complications
Prazo: Up to 12 months
Documentation of possible, probable, or definite catheter-related complications
Up to 12 months
Number of catheter related complications after catheter removal
Prazo: Up to 12 months
Documentation of possible, probable, or definite catheter-related complications
Up to 12 months
Change in the spatial distribution of intratumorally-administered topotecan at serial timepoints using a gadolinium-based contrast agent, as determined by MRI scan
Prazo: Up to 12 months
Up to 12 months
Changes in the spatial distribution of intratumorally-administered topotecan associated with changes in the infusion rate, as determined by MRI scan
Prazo: Up to 12 months
Up to 12 months
Changes in the spatial distribution of intratumorally-administered topotecan at serial timepoints using volumetric magnetic resonance imaging, as determined by MRI scan
Prazo: Up to 12 months
Up to 12 months
Changes in the spatial distribution of intratumorally-administered topotecan at serial timepoints using three-dimensional image reconstruction, as determined by MRI scan
Prazo: Up to 12 months
Up to 12 months
Changes in the spatial distribution of intratumorally-administered topotecan associated with changes in the infusion concentration, as determined by MRI scan
Prazo: Up to 12 months
Up to 12 months
Changes in the spatial distribution of intratumorally-administered topotecan associated with changes in the infusion duration, as determined by MRI scan
Prazo: Up to 12 months
Up to 12 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Number of Participants with response as measured by the Response Assessment in Neuro-Oncology (RANO) Criteria
Prazo: Up to 12 months
Response includes objective response rate (ORR), median progression-free survival (PFS), proportion progression-free at six months (PFS-6), and median overall survival (OS)
Up to 12 months
Safety as measured by the common terminology criteria for adverse events (CTCAE)
Prazo: Up to 12 months
Safety will be determined through adverse events by arm
Up to 12 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Michael Vogelbaum, MD, PhD

Colaboradores

Infuseon Therapeutics, Inc.

Investigadores

  • Investigador principal: Michael A. Vogelbaum, MD, PhD, Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

3 de novembro de 2017

Conclusão Primária (Real)

19 de novembro de 2018

Conclusão do estudo (Real)

19 de novembro de 2018

Datas de inscrição no estudo

Enviado pela primeira vez

13 de junho de 2017

Enviado pela primeira vez que atendeu aos critérios de CQ

17 de junho de 2017

Primeira postagem (Real)

20 de junho de 2017

Atualizações de registro de estudo

Última Atualização Postada (Real)

1 de março de 2019

Última atualização enviada que atendeu aos critérios de controle de qualidade

28 de fevereiro de 2019

Última verificação

1 de fevereiro de 2019

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • INFT1317

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Sim

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Ensaios clínicos em Topotecan (<=8cc)

Pesquisar ensaios semelhantes

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

CROs by country

CROs in Ethiopia

Condições

Doenças Raras

Intervenções de drogas

Suplementos Alimentares

Patrocinador / Colaboradores

Localizações

Se inscrever